Mutations in RECQL4 are present in approximately one third of the clinically diagnosed RTS patients (RTS type II) and these patients phenotype is characterised by poikiloderma, bone defects and an incresased risk of osteosarcoma. This evidence concerns the gene RECQL4 and Rothmund-Thomson syndrome.